New Quality of Life Study Sponsored by Zoetis Will Assess 900 Canine Patients Using the Voyce Health Monitor™
CHANTILLY, Va., Nov. 16, 2015 /PRNewswire/ -- More than 900 dogs newly diagnosed with osteoarthritis will take part in a new research study sponsored by Zoetis. Over the course of a year, the study aims to collect measurable data and candid insights concerning dosage and compliance in pain management. Using the patented Voyce Health Monitor, pet owners will report "quality of life scores" – these scores equate to a validated measure of how the dog "feels."
"The ability to gather reliable information is critical when conducting studies, especially involving animals who may be in pain or struggling," said Andrea K Wright DVM, MVSc, MBA Associate Director of Outcomes Research of Zoetis. "With this latest study, we aim to discover new insights so that we can better support the health and well-being of dogs coping with osteoarthritis. Thanks to the innovative tools from Voyce Pro™, objective biomedical data will be gathered right from the pet's home environment in a non-invasive way. With the Voyce Health Monitor, we'll be able to track parameters that help indicate the quality of life and level of pain, without disrupting each dog's daily routine."
The Voyce Health Monitor is worn like a collar and uses non-invasive sensors with no skin contact necessary to collect health data such as resting heart and respiratory rates, activity and intensity metrics, quality of rest and more. These are important metrics when monitoring arthritis treatment, as they provide indicators of improved comfort and well-being, such as: increased or maintained activity and intensity, stabilization of resting heart rate and decreased sleep disruptions.
Additionally, veterinarians and researchers involved in the study will be able to monitor participating canine patients in real-time through the Voyce Pro Wellness Monitoring Program™. This monitoring platform enables users to gather objective data remotely - at anytime, anywhere – through each activated Voyce Health Monitor.
"Technology has driven medication management to a new level and we are proud to be participating in this important study with Zoetis," said Michael Stanfield, Chairman and CEO of Voyce. "The accuracy and reliability of the data collected using this new technology will enable the observation and understanding of animals' biometric responses to medication, or the lack thereof. Using this data, companies like Zoetis can continually enhance their products and the manner in which customers comply with recommended usage guidelines."
For more information about the Voyce Health Monitor and the Voyce Pro Wellness Monitoring Program for Veterinary Professionals, please visit voycepro.com.
Voyce is comprised of a diverse team of passionate individuals committed to building a suite of unique products and services for the companion animal market. As part of its comprehensive approach to pet wellness, Voyce brings a new era of personalized care to pets - where pet parents and veterinarians are empowered with unprecedented insights and tangible information about the health and wellbeing of each individual dog. I4C Innovations, dba Voyce, is a wholly owned subsidiary of Intersections Inc. (Nasdaq: INTX) and is headquartered in Chantilly, VA. For more information, please visit voyce.com.
Intersections Inc. (Nasdaq: INTX) provides innovative, information-based solutions that help consumers manage risks and make better-informed life decisions. Under its Identity Guard® brand and other brands, the company helps consumers monitor, manage and protect against the risks associated with their identities and personal information. The company's subsidiary Intersections Insurance Services provides insurance and other services that help consumers manage risks and achieve personal goals. The company's subsidiary Voyce™ is a pet health monitoring platform and information management service that collects, translates, monitors and distributes wellness indicators to veterinarians, the service industry for dogs, and consumers including key vital signs like resting respiratory and heart rates, rest and quality of rest, activity and the intensity of that activity, and caloric burn. To learn more, visit intersections.com.
Zoetis (zo-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenues of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetisUS.com.
SOURCE Intersections Inc.
Share this article